Viatris launches generic for AstraZeneca’s asthma and COPD drug Symbicort

As­traZeneca’s block­buster asth­ma and COPD drug Sym­bi­cort, which brought in $2.5 bil­lion for the phar­ma gi­ant in 2022, now has a gener­ics com­peti­tor from Vi­a­tris.

Vi­a­tris teamed up with Kinde­va Drug De­liv­ery to launch its own in­halant Brey­na, a com­plex drug-de­vice com­bo that marks the first out­side gener­ic to come to mar­ket to com­pete with Sym­bi­cort, Vi­a­tris an­nounced Mon­day. As­traZeneca launched an au­tho­rized gener­ic in Jan­u­ary 2020.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters